This is a phase II Randomized comparison clinical trial of PD-1 inhabitor activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced liver cancer. And the aim of this research is to study the clinical efficacy and safety of PD-1 activated CIK armed with anti-CD3-MUC1 bispecific antibody for liver cancer.